11:26 AM EDT, 10/21/2025 (MT Newswires) -- Danaher's ( DHR ) fiscal third-quarter results came in stronger than Wall Street's forecasts, while the medical equipment maker reiterated its full-year earnings guidance.

Adjusted earnings rose to $1.89 per share for the quarter ended Sept. 26 from $1.71 a year earlier, surpassing the FactSet-polled consensus of $1.72. Sales grew 4.5% to $6.05 billion, while analysts expected $6 billion.

Core sales grew 3%, driven by the biotechnology and diagnostics segments.

"(Danaher Business System)-driven execution, paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid, enabled us to exceed our revenue, earnings and cash flow expectations," Chief Executive Rainer Blair said in the earnings release.

Cepheid is Danaher's ( DHR ) molecular diagnostics company.

The company continues to expect 2025 adjusted EPS of $7.70 to $7.80, assuming low-single-digit growth in core revenue. It previously projected non-GAAP revenue to rise 3% in 2025. Analysts are looking for full-year EPS of $7.78 on revenue of $24.71 billion.

Danaher's ( DHR ) shares were up 8.9% in Tuesday trade, trimming year-to-date losses to 1.2%.

For 2026, the company expects core revenue growth in the 3% to 6% range, "assuming modest recovery across our end markets," Blair said on an earnings conference call, according to a FactSet transcript.

"We expect the operating leverage on anticipated core revenue growth and the benefit of our 2025 productivity initiatives to drive more than 100 basis points of adjusted operating profit margin expansion, which would result in high single-digit adjusted earnings per share growth," he said.

Analysts are projecting EPS of $8.50 for next year on revenue of $26.03 billion.

"Looking across the portfolio, we're assuming bioprocessing growth trends remain at levels consistent with 2025, including continued strength in consumables driven by healthy growth in monoclonal antibody demand and our strong positioning across the biologics workflow," Blair said on the call.

Price: 225.88, Change: +17.49, Percent Change: +8.39